Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
3. Device tax will “absolutely, directly, negatively influence job growth”
The medical device tax will have an inevitably negative effect on jobs in the medtech industry, BioMimetic Therapeutics founder Sam Lynch says.
2. Allergan drops $958M on migraine drug maker MAP Pharma
Cosmetic medicine giant Allergan will pay nearly $1 billion for MAP Pharmaceuticals, maker of experimental migraine drug Levadex.
1. 1 in 3 metal hips may fail in under 5 years, J&J analysis finds
Nearly 40% of Johnson & Johnson subsidiary DePuy Orthopaedics’ recalled ASR metal-on-metal hip implants may fail within 5 years, according to an internal analysis uncovered during a patient injury lawsuit.
